Inquiry Basket
Loading ......
Teclistamab is a first-in-class bispecific antibody that targets both B-cell maturation antigen (BCMA) and CD3, representing a transformative therapy for patients with relapsed or refractory multiple myeloma. Structurally, Teclistamab is a humanized immunoglobulin gamma four (IgG4)-based bispecific antibody engineered to redirect T cells to eliminate BCMA-expressing malignant plasma cells. This innovative mechanism of action has demonstrated remarkable clinical efficacy in heavily pretreated patients who have exhausted multiple prior lines of therapy, including immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies.The successful clinical use of Teclistamab depends on robust bioanalytical methods to support pharmacokinetic studies, immunogenicity assessments, and therapeutic monitoring. As a bispecific antibody, Teclistamab presents unique bioanalytical challenges. Accurate quantification of Teclistamab concentrations in biological matrices is essential for understanding the relationship between drug exposure and clinical response. Additionally, detection of anti-Teclistamab antibodies is critical for evaluating immunogenicity, as treatment-emergent anti-drug antibodies can alter pharmacokinetics, reduce efficacy, and potentially trigger adverse events.
Figure 1.Teclistamab Quantification Reliable ELISA for Pharmacokinetic Studies.
B-cell maturation antigen is a member of the tumor necrosis factor receptor superfamily that plays a critical role in plasma cell survival. Under normal physiological conditions, BCMA expression is restricted to plasma cells and a subset of mature B cells, with minimal expression on other tissues. In multiple myeloma, BCMA is uniformly and highly expressed on malignant plasma cells across all stages of the disease, making it an ideal target for immunotherapy. The restricted expression pattern of BCMA provides a favorable therapeutic window. Unlike other targets expressed on hematopoietic stem cells or other immune populations, BCMA targeting spares most normal tissues. Additionally, BCMA is shed from the surface of myeloma cells, generating soluble BCMA that can be detected in serum and used as a pharmacodynamic biomarker of treatment response.
Teclistamab binds simultaneously to BCMA on multiple myeloma cells and to CD3 on T cells. The CD3-binding domain of Teclistamab engages the CD3 epsilon chain of the T-cell receptor complex, while the BCMA-binding domain recognizes the extracellular domain of BCMA on target cells. This dual binding physically links T cells to myeloma cells, forcing the formation of a cytolytic synapse regardless of the T-cell receptor specificity. Upon synapse formation, T cells become activated through signaling pathways that resemble those triggered by native antigen recognition. Activated T cells upregulate activation markers such as CD25 and CD69, proliferate robustly, and release cytotoxic granules containing perforin and granzymes. These granules penetrate the target myeloma cell membrane, inducing apoptotic cell death. The activated T cells also produce pro-inflammatory cytokines including interferon-gamma, tumor necrosis factor-alpha, and interleukin-6, which contribute to the anti-tumor immune response. A distinguishing feature of Teclistamab is its IgG4 backbone. Unlike IgG1 antibodies that engage Fc gamma receptors and complement, IgG4 has reduced effector function, minimizing the risk of Fc-mediated toxicities such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. This design focuses the mechanism of action on T-cell redirection, which is the intended therapeutic effect.
Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. In the pivotal clinical trial, Teclistamab demonstrated high overall response rates, with a substantial proportion of patients achieving complete remissions or better. The durability of responses has been notable, with many responding patients maintaining remission at long-term follow-up. The safety profile of Teclistamab is characterized by cytokine release syndrome, which is typically low-grade and confined to the first treatment cycle. Infections, including upper respiratory tract infections and pneumonia, are the most common adverse events and require appropriate monitoring and prophylaxis.
| Key Molecular Targets | Details |
| Total Teclistamab ELISA Kit | The Total Teclistamab ELISA Kit is designed for the quantitative determination of total Teclistamab concentrations in human serum or plasma, including both free drug and drug bound to BCMA or CD3. Key Features
|
| Anti-Teclistamab ELISA Kit | The Anti-Teclistamab ELISA Kit is designed for the detection and semi-quantitative determination of anti-Teclistamab antibodies in human serum or plasma. This kit supports comprehensive immunogenicity assessment in clinical research and regulatory submissions. Applications
|
Bispecific antibody bioanalysis presents unique challenges distinct from traditional antibody detection, and teclistamab's BCMA/CD3 dual-target structure amplifies these analytical complexities. Effective teclistamab monitoring requires differentiation between total circulating drug levels and biologically active drug fractions, alongside elimination of common matrix interferences.
First, teclistamab exists in multiple in vivo forms: free unbound active drug, BCMA-target-bound inactive drug, and ADA-bound drug complexes. Total drug quantification reflects overall systemic exposure for PK profiling, while active drug levels directly correlate with therapeutic efficacy and target saturation. Second, human biological matrices contain endogenous immunoglobulins, proteases, and pre-existing antibodies that cause non-specific binding and assay interference, compromising data accuracy. Third, FDA and EMA regulatory frameworks mandate fully validated, precise bioanalytical methods for bispecific therapeutics to support clinical trial data submission and dose optimization. Generic ELISA platforms cannot distinguish teclistamab from endogenous antibodies or differentiate functional drug states, leading to unreliable PK/PD data. Our purpose-built teclistamab ELISA kits resolve these pain points, delivering targeted, regulatory-ready quantification to support every stage of teclistamab drug development and clinical monitoring.
Teclistamab is a first-in-class BCMAxCD3 bispecific antibody that has transformed the treatment landscape for relapsed or refractory multiple myeloma, offering deep and durable responses in heavily pretreated patients. The successful clinical development and use of Teclistamab depend on robust bioanalytical methods to support pharmacokinetic characterization and immunogenicity assessment. The Total Teclistamab ELISA Kit provides a validated, sensitive, and specific solution for quantifying total drug concentrations, enabling accurate exposure assessment regardless of target binding status. The Anti-Teclistamab ELISA Kit enables comprehensive immunogenicity monitoring, detecting anti-drug antibodies that could impact drug exposure and efficacy. Together, these kits provide a complete bioanalytical toolkit for researchers and clinicians working with Teclistamab across all stages of development and clinical use.
| Cat. No. | Product Name | Species Reactivity | Detection Method | |
| DEIA-JY25048 | Total Teclistamab ELISA Kit | Human | ELISA | Inquiry |
| DEIA-JY25066 | Anti-Teclistamab ELISA Kit | Human | ELISA | Inquiry |
Loading ......
